AAAAAA
Results: 1-25/28
Authors:
Yarasheski, KE
Tebas, P
Stanerson, E
Claxton, S
Marin, D
Bae, K
Kennedy, M
Tantisiriwat, W
Powderly, WG
Citation: Ke. Yarasheski et al., Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy, J APP PHYSL, 90(1), 2001, pp. 133-138
Authors:
Bersoff-Matcha, SJ
Miller, WC
Aberg, JA
van der Horst, C
Hamrick, HJ
Powderly, WG
Mundy, LM
Citation: Sj. Bersoff-matcha et al., Sex differences in nevirapine rash, CLIN INF D, 32(1), 2001, pp. 124-129
Authors:
Tantisiriwat, W
Tebas, P
Polish, LB
Casabar, E
Powderly, WG
Fichtenbaum, CJ
Citation: W. Tantisiriwat et al., Elevated lactate levels in hospitalized persons with HIV infection, AIDS RES H, 17(3), 2001, pp. 195-201
Authors:
Tebas, P
Henry, K
Nease, R
Murphy, R
Phair, J
Powderly, WG
Citation: P. Tebas et al., Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy, AIDS, 15(5), 2001, pp. 591-599
Authors:
Koletar, SL
Heald, AE
Finkelstein, D
Hafner, R
Currier, JS
McCutchan, JA
Vallee, M
Torriani, FJ
Powderly, WG
Fass, RJ
Murphy, RL
Citation: Sl. Koletar et al., A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 X 10(6)/I, AIDS, 15(12), 2001, pp. 1509-1515
Authors:
Powderly, WG
Citation: Wg. Powderly, Current approaches to treatment for HIV-1 infection, J NEUROVIRO, 6, 2000, pp. S8-S13
Authors:
Powderly, WG
Citation: Wg. Powderly, Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy, CLIN INF D, 31(2), 2000, pp. 597-601
Authors:
Fichtenbaum, CJ
Koletar, S
Yiannoutsos, C
Holland, F
Pottage, J
Cohn, SE
Walawander, A
Frame, P
Feinberg, J
Saag, M
Van der Horst, C
Powderly, WG
Citation: Cj. Fichtenbaum et al., Refractory mucosal candidiasis in advanced human immunodeficiency virus infection, CLIN INF D, 30(5), 2000, pp. 749-756
Authors:
Saag, MS
Graybill, RJ
Larsen, RA
Pappas, PG
Perfect, JR
Powderly, WG
Sobel, JD
Dismukes, WE
Citation: Ms. Saag et al., Practice guidelines for the management of cryptococcal disease, CLIN INF D, 30(4), 2000, pp. 710-718
Authors:
Tantisiriwat, W
Powderly, WG
Citation: W. Tantisiriwat et Wg. Powderly, Prophylaxis of opportunistic infections, INF DIS CL, 14(4), 2000, pp. 929
Authors:
Arribas, JR
Hernandez-Albujar, S
Gonzalez-Garcia, JJ
Pena, JM
Gonzalez, A
Canedo, T
Madero, R
Vazquez, JJ
Powderly, WG
Citation: Jr. Arribas et al., Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis, AIDS, 14(8), 2000, pp. 979-985
Authors:
Fichtenbaum, CJ
Zackin, R
Rajicic, N
Powderly, WG
Wheat, LJ
Zingman, BS
Citation: Cj. Fichtenbaum et al., Amphotericin B oral suspension for fluconazole-refractory oral candidiasisin persons with HIV infection, AIDS, 14(7), 2000, pp. 845-852
Authors:
Tebas, P
Powderly, WG
Claxton, S
Marin, D
Tantisiriwat, W
Teitelbaum, SL
Yarasheski, KE
Citation: P. Tebas et al., Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy, AIDS, 14(4), 2000, pp. F63-F67
Authors:
Powderly, WG
Citation: Wg. Powderly, Current approach to the acute management of cryptococcal infections, J INFECTION, 41(1), 2000, pp. 18-22
Authors:
Benson, CA
Williams, PL
Cohn, DL
Becker, S
Hojczyk, P
Nevin, T
Korvick, JA
Heifets, L
Child, CC
Lederman, MM
Reichman, RC
Powderly, WG
Notario, GF
Wynne, BA
Hafner, R
Citation: Ca. Benson et al., Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial, J INFEC DIS, 181(4), 2000, pp. 1289-1297
Authors:
Yarasheski, KE
Tebas, P
Sigmund, C
Dagogo-Jack, S
Bohrer, A
Turk, J
Halban, PA
Cryer, PE
Powderly, WG
Citation: Ke. Yarasheski et al., Insulin resistance in HIV protease inhibitor-associated diabetes, J ACQ IMM D, 21(3), 1999, pp. 209-216
Authors:
Fichtenbaum, CJ
German, M
Dunagan, WC
Fraser, VJ
Medoff, G
Diego, J
Powderly, WG
Citation: Cj. Fichtenbaum et al., A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B, CLIN INF D, 29(6), 1999, pp. 1551-1556
Authors:
Tantisiriwat, W
Tebas, P
Clifford, DB
Powderly, WG
Fichtenbaum, CJ
Citation: W. Tantisiriwat et al., Progressive multifocal leukoencephalopathy in patients with AIDS receivinghighly active antiretroviral therapy, CLIN INF D, 28(5), 1999, pp. 1152-1154
Authors:
Fichtenbaum, CJ
Powderly, WG
Citation: Cj. Fichtenbaum et Wg. Powderly, Refractory mucosal candidiasis in patients with human immunodeficiency virus infection - Reply, CLIN INF D, 28(2), 1999, pp. 408-408
Authors:
Powderly, WG
Citation: Wg. Powderly, Treatment of infection due to Mycobacterium avium complex, PEDIAT INF, 18(5), 1999, pp. 468-469
Authors:
Powderly, WG
Gallant, JE
Ghannoum, MA
Mayer, KH
Navarro, EE
Perfect, JR
Citation: Wg. Powderly et al., Oropharyngeal candidiasis in patients with HIV: Suggested guidelines for therapy, AIDS RES H, 15(18), 1999, pp. 1619-1623
Authors:
Powderly, WG
Mayer, KH
Perfect, JR
Citation: Wg. Powderly et al., Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: A critical reassessment, AIDS RES H, 15(16), 1999, pp. 1405-1412
Authors:
Tebas, P
Patick, AK
Kane, EM
Klebert, MK
Simpson, JH
Erice, A
Powderly, WG
Henry, K
Citation: P. Tebas et al., Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir, AIDS, 13(2), 1999, pp. F23-F28
Authors:
Powderly, WG
Saag, MS
Chapman, S
Yu, G
Quart, B
Clendeninn, NJ
Citation: Wg. Powderly et al., Predictors of optimal virological response to potent antiretroviral therapy, AIDS, 13(14), 1999, pp. 1873-1880
Authors:
Powderly, WG
Citation: Wg. Powderly, The interaction of opportunistic infections and HIV replication, AIDS, 13(13), 1999, pp. 1603-1606